Verona Pharma plc
VRNA
$65.46
$0.681.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -139.36% | -192.52% | -704.30% | -54.06% | -35.22% |
| Total Depreciation and Amortization | 24.52% | 71.61% | 71.97% | 67.52% | 37.75% |
| Total Amortization of Deferred Charges | 3,953.85% | 654.37% | -- | -- | -83.75% |
| Total Other Non-Cash Items | 463.69% | -264.30% | 830.56% | 34.79% | 71.13% |
| Change in Net Operating Assets | -12,096.77% | -149.63% | 174.44% | -1.13% | -75.40% |
| Cash from Operations | -177.22% | -392.30% | 19.75% | -135.39% | -34.43% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -- | -- | -- | 187.12% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 7,541.67% | -100.00% | -98.61% | -- |
| Repurchase of Common Stock | 9.07% | -- | -- | -- | -100.26% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | 93.88% |
| Cash from Financing | 292.12% | -14,864.58% | 134,441.94% | -104.55% | 818.59% |
| Foreign Exchange rate Adjustments | -234.30% | 273.46% | -96.79% | -120.58% | -36.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 342.29% | -413.13% | 823.69% | -126.56% | 471.86% |